Under these conditions, the ???end-target chemoattractants??? such as fMLF, that are more capable of activating terminal functions of neutrophils, seem to prevail over ???intermediary chemoattractants??? such as IL-8 and other chemokines present at the site of inflammation (Heit et al., 2002).